Novel APOC3 gene-silencing agents currently in development could reduce coronary heart disease (CHD) risk by approximately 25% during a 5-year outcomes trial. This conclusion is based on results from a polygenic score (PGS)-based model to investigate if the degree of triglyceride rich lipoprotein (TRL)/remnant reduction seen with APOC3 gene-silencing would lead to a meaningful reduction in CHD risk.
